Myelotoxicity is a very common treatment-related adverse effect for patients receiving systemic chemotherapy, and patients receiving radiotherapy directed to body regions rich in bone marrow and hematopoiesis activity. Myelotoxicity or myelosuppression is the most common dose-limiting toxicity in cancer treatment with cytotoxic agents, and often leads to dose reduction, dose delay or discontinuation of treatment, limiting the therapeutic effect.
Zymeron develops molecularly targeted prophylactic drug for the prevention of radiotherapy-induced myelosuppression, chemotherapy-induced myelosuppression, and hematopoietic acute radiation syndrome (ARS). The drug is currently being investigated in an injectable formulation in multiple animal models. The drug provides broad spectrum protection for multi-lineages of the hematopoietic stem cells to prevent neutropenia, anemia and thrombocytopenia. Radiation-induced myelosuppression and chemotherapy-induced myelosuppression represent multi-billion dollar markets; however most current healthcare solutions are for post-treatment and there is no widely available preventive medicine that could maximize the cancer treatment effect and eliminate or reduce their toxicity to the bone marrow.
Zymeron (www.zymeron.com) is a research-based biotechnology company that discovers, develops and commercializes innovative technologies to deliver products and solutions with step-change performance. Zymeron operates as an innovation engine to advance portfolios of technologies to detect, prevent, and treat infectious diseases, immune disorders and emerging threats, and to improve the sustainability of critical life support and health maintenance.